%0 Journal Article
%T Next-generation CD40 agonists for cancer immunotherapy.
%A Andersson H
%A Nyesiga B
%A Hermodsson T
%A Enell Smith K
%A Hägerbrand K
%A Lindstedt M
%A Ellmark P
%J Expert Opin Biol Ther
%V 24
%N 5
%D 2024 May 23
%M 38764393
%F 5.589
%R 10.1080/14712598.2024.2357714
%X UNASSIGNED: There is a need for new therapies that can enhance response rates and broaden the number of cancer indications where immunotherapies provide clinical benefit. CD40 targeting therapies provide an opportunity to meet this need by promoting priming of tumor-specific T cells and reverting the suppressive tumor microenvironment. This is supported by emerging clinical evidence demonstrating the benefits of immunotherapy with CD40 antibodies in combination with standard of care chemotherapy.
UNASSIGNED: This review is focused on the coming wave of next-generation CD40 agonists aiming to improve efficacy and safety, using new approaches and formats beyond monospecific antibodies. Further, the current understanding of the role of different CD40 expressing immune cell populations in the tumor microenvironment is reviewed.
UNASSIGNED: There are multiple promising next-generation approaches beyond monospecific antibodies targeting CD40 in immuno-oncology. Enhancing efficacy is the most important driver for this development, and approaches that maximize the ability of CD40 to both remodel the tumor microenvironment and boost the anti-tumor T cell response provide great opportunities to benefit cancer patients. Enhanced understanding of the role of different CD40 expressing immune cells in the tumor microenvironment may facilitate more efficient clinical development of these compounds.